Private equity now sells assets to itself at a record clip. If the point of a market is arms-length price discovery, this is a paradox. Continuation vehicles, the GP-led funds used to move portfolio companies from an old fund into a new one, are set to account for roughly a fifth of exits next year. That is not a footnote. It is a regime. The headline claim is liquidity and alignment. The hidden reality is a closed loop where marks are set inside the house and time is the raw material. Systems that feed on their own signals can run for a long time, until a small shock reveals the true load-bearing capacity. Bridges do not fail at the blueprint. They fail at the first unexpected gust.
Continuation vehicles exist to solve a simple problem: there are not enough willing third-party buyers at the price managers want, at the time they need to return cash. So assets are shifted into a fresh pot with new terms, new fees, and more time. In 2025, nearly 20 percent of private equity exits involved these GP-led structures. The pitch is rational. Good assets deserve more time. Public markets are shut. Strategic buyers are cautious. Why sell at a discount when you can refinance the holding inside the ecosystem. On paper, everyone wins. Original investors get a choice: take cash or roll. New investors get access to a seasoned asset. Managers keep control. But like any complex mechanism, the failure modes are not on the surface. They live in incentives and in who sets the price.
In a GP-led deal, the manager sits on both sides of the table. Advisors and fairness opinions are meant to police the process. They help. They do not remove the central conflict: the referee works for one of the teams. The Financial Times reported on investors in a Triton Partners fund who took cash rather than roll into a continuation vehicle and later missed out on further upside. That result can be read two ways. Either the manager correctly saw latent value and gave investors a fair choice. Or the process priced the asset using inside optimism, setting up a heads-I-win, tails-you-lose dynamic. If the GP wants the asset and controls the auction, the fair price becomes a fog. A second bite at carry and fees adds to the bias. Time is sold at a premium. Who pays it is a function of information and governance, not just asset quality.
The promise of liquidity is not the same thing as an open market. Liquidity is only real if an independent buyer with fresh underwriting is willing to set the price. In a continuation vehicle, the buyer is a new pool curated by the same sponsor, often financed with leverage and bridged by short-term facilities. Sometimes existing limited partners are the liquidity. The cash feels like an exit. Economically, it can be a transfer from one sleeve to another. Critics warn of Ponzi-like dynamics because each new vehicle needs high marks to attract capital. The label is crude, but the pressure is accurate. If subsequent fundraising slows or credit tightens, the chain stops and the marks must meet the market. The more links in the chain, the higher the system’s sensitivity to a single weak link. When price signals come from inside the system, fragility grows quietly.
Think of a GP-led deal as a repeated game with private information. The manager wants to avoid a down mark and preserve reputation for realized gains. The LP faces a coordination problem. If everyone rolls, maybe the value is there. If most take cash, maybe the asset is being warehoused. No one wants to be the last holder of a mediocre company in its third fund home. So LPs hedge, or they capitulate to optionality they do not control. Fee structures amplify this. Managers can reset carry even on assets they already own, charge transaction fees to a fund buying from a sister vehicle, and extend monitoring fees. All of this can be disclosed and still shift payoffs in favor of the GP. In game theory, equilibrium emerges from incentives, not narratives. If the equilibrium pays the house more for time, the house will sell time.
This is not the first time structure has outrun substance in private equity. In 2006, the industry’s club deals drew antitrust scrutiny for how syndicated bidding might dampen prices. CVs are not price-fixing. They rhyme with the same concern: when insiders coordinate around assets, outsiders struggle to know the real clearing price. Legal memos call the conflicts manageable with process, and process helps. But valuation committees, auditors, and fairness opinions still rely on manager inputs. If marks drift up in straight lines while public comparables wobble, that is not proof of skill. It may be proof of insulation. The longer assets live inside sponsor-managed vehicles, the more performance becomes a story about model assumptions, discount rates, and treatment of one-off adjustments. Markets fail not in the moment of panic, but in the years of quiet smoothing that precede it.
The rise of continuation vehicles fits a broader shift. Large firms went public, built distribution, and turned into product platforms. The business now optimizes for assets under management, not just realized gains. CVs extend duration, stack fees, and finance the middle with NAV loans and subscription lines. That is leverage on leverage. In good times, it looks like capital efficiency. In stress, it looks like a pressure vessel with a single relief valve: new fundraising. If the IPO window stays narrow and strategic buyers remain selective, sponsors will sell to each other or to themselves. That recycles risk within the same small set of hands. Correlations will rise when it matters, and LPs who think they are diversified by manager may discover they are concentrated by structure. Systems built on short-term funding and long-duration promises rarely end with a graceful unwind.
The deeper issue is not legal. It is human. Investors like the feeling of control that a GP-led process provides: known asset, known team, clear path to value creation. That preference is understandable and often rational. It is also the seed of fragility. When we prefer the familiar over the uncertain, we accept lower risk premiums for higher structural risk. We trade the rough price discovery of an open market for smooth marks and a plan. Probability does not reward plans. It rewards options. Antifragile portfolios gain from volatility and from the entry of true outsiders. CVs tend to move optionality from LPs to GPs. Cash-out investors crystallize middling returns. Rollovers pay to keep the dream alive and tie their outcome to the manager’s future fundraising, credit conditions, and a narrow exit funnel. That is not a catastrophe. It is simply not a free lunch.
Invert the sales pitch and see what breaks. Assume the assets inside CVs are strong. Would they not clear in a competitive process with independent buyers at prices that do not require fee resets and complex bridge financing. Assume the assets are average. Does concentrating control, extending duration, and layering fees improve the outcome for existing LPs. Assume rates stay higher for longer and public markets remain picky. What does the third or fourth sponsor-to-sponsor sale look like in that world. Base rates matter. Most cycles end not with flames but with a slow suffocation of liquidity. The longer a system depends on internal buyers to prove external value, the more it mistakes motion for progress. That is the unseen fragility in GP-led secondaries. The numbers look fine until an outside bid forces everyone to mark to the world as it is, not as they need it to be.
